SCHEMBL24944164

SCHEMBL24944164

CNc1nc(Nc2ccc(N3CCOCC3)c(C)c2F)c(C(N)=O)nc1-c1cncc2c1ncn2C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RET P07949 7/20 0.36
▸ ROS1 P08922 7/20 0.36
▸ FLT3 P36888 7/20 0.36
▸ EML4 Q9HC35 6/20 0.36
▸ ALK Q9UM73 6/20 0.36
▸ MAPK9 P45984 6/20 0.35
▸ MAPK10 P53779 6/20 0.35
▸ MAPK8 P45983 3/20 0.33
▸ LRRK2 Q5S007 1/20 0.33
▸ KCNH2 Q12809 1/20 0.32
▸ SYK P43405 3/20 0.32
▸ IRAK4 Q9NWZ3 2/20 0.32
▸ BMPR1B O00238 1/20 0.32
▸ PLK4 O00444 1/20 0.32
▸ CIT O14578 1/20 0.32
▸ AURKA O14965 1/20 0.32
▸ GAK O14976 1/20 0.32
▸ EPHB6 O15197 1/20 0.32
▸ RIPK2 O43353 1/20 0.32
▸ BUB1 O43683 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24944442 0.94 RET (0.37) RETROS1FLT3EML4ALK
SCHEMBL30205667 0.92 MAPK9 (0.37) RETROS1FLT3EML4ALK
SCHEMBL30205976 0.92 LRRK2 (0.35) LRRK2EGFR
SCHEMBL29173615 0.92 LRRK2 (0.35) LRRK2EGFR
SCHEMBL24944756 0.92 MAPK9 (0.37) RETROS1FLT3EML4ALK
SCHEMBL24943794 0.89 RET (0.38) RETROS1FLT3EML4ALK
SCHEMBL24944367 0.88 MAPK9 (0.48) RETROS1FLT3EML4ALK
SCHEMBL30205517 0.88 MAPK9 (0.48) RETROS1FLT3EML4ALK
SCHEMBL29173428 0.86 LRRK2 (0.36) RETROS1FLT3ALKMAPK9
SCHEMBL30206349 0.86 LRRK2 (0.36) RETROS1FLT3ALKMAPK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4373817-B1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2025-05-21 — — EP claimed
EP-4373817-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER Astrazeneca AB (SE) 2024-05-29 — — EP claimed
CN-117693503-A Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer 阿斯利康(瑞典)有限公司 2024-03-12 — — CN claimed
WO-2023001794-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2023-01-26 — — WO claimed
EP-4373817-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER Astrazeneca AB (SE) 2024-05-29 — — EP disclosed
CN-117693503-A Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer 阿斯利康(瑞典)有限公司 2024-03-12 — — CN disclosed
WO-2023001794-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2023-01-26 — — WO disclosed
WO-2023001794-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2023-01-26 — — WO disclosed
Send feedback